Chalkis Health Industry (000972.SZ) announced its performance forecast for the first three quarters of 2024 on October 14th, with a net income loss attributable to shareholders of the listed company ranging from 50 million yuan to 35 million yuan, compared to a profit of 43.0116 million yuan in the same period last year; after deducting non-recurring gains and losses, the net income loss is between 50 million yuan and 35 million yuan, compared to a profit of 42.1653 million yuan in the same period last year; the basic earnings per share are expected to be a loss of 0.0648 yuan/share to 0.0454 yuan/share; revenue is expected to be between 260 million yuan and 330 million yuan, a decrease of 24.21% to 3.81% compared to the same period last year; revenue after deductions is expected to be between 240 million yuan and 310 million yuan, a decrease of 27.41% to 6.24% compared to the same period last year.
Due to the impact of the Red Sea-Suez Canal shipping crisis, domestic tomato processing companies have seen a significant decrease in overseas customers deferring delivery, a reduction in the number of export ships, and an extension of the delivery-departure-payment cycle for goods stored in ports; this impact has led to a decrease in sales prices and volumes of the company's main product, bulk tomato sauce, compared to the same period last year. In the case of reduced sales volume and lower gross margin, the overall net profit of the company has decreased significantly. At the same time, inventory valuation reserves have been provisioned in accordance with accounting standards. The company has already begun actively developing flagship products in the fast-moving consumer goods and health product sectors, focusing on increasing domestic sales efforts, and gradually expanding the domestic market marketing channels.
